Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden

View Full Paper
Ask AI
Bookmark
Share

Authors

EREva RadovaOVOndrej VenglárLBLucie Broskevičová

Discussion

Loading...

Member takes

Overview

Comparative gene expression analysis of CTCs and plasma cells points to mechanisms of egression in multiple myeloma.

Key Points

  • This research aims to explore the transcriptomic differences between circulating tumor cells and plasma cells in multiple myeloma.
  • Analyzed PB samples from 29 NDMM patients using EuroFlow protocol and next-generation flow cytometry.
  • Paired CTCs and BM plasma cells were isolated using FACS and MACS techniques.
  • Conducted differential gene expression analysis with DESeq2 and assessed associations with survival outcomes.
  • Computed a CTC-like score weighted by gene expression values for assessing cytogenetic features.
  • Identified 1,142 differentially expressed genes between CTCs and BM plasma cells.
  • CTCs exhibited reduced expression of proliferation-related genes and increased CTC-like scores compared to BM plasma cells.
  • Higher CTC-like scores were associated with specific cytogenetic alterations, including 1q gain and t(14;16).

Cite This Study

Radova et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5fdhttps://doi.org/10.1182/blood-2025-3927
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1B03 | TRANSCRIPTOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCS) IN MULTIPLE MYELOMA REVEALS EGRESSION-ASSOCIATED PROFILE RELATED TO CTC BURDEN2026
  2. 2Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma.2025 · 9 citations
  3. 3Phenotypic evolution of circulating tumor plasma cells across MGUS, SMM and multiple myeloma2025
  4. 4Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights2025
  5. 5B04 | BLOOD-BASED RISK STRATIFICATION OF MYELOMA PATIENTS USING CIRCULATING TUMOR CELLS: RESULTS FROM THE EUROPEAN CTC CONSORTIUM2026